WAM
ACAD icon

Wakefield Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Wakefield Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35,390
Closed -$1.11M – 146
2023
Q4 		$1.11M Buy
+35,390
New +$845K 0.41% 66

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wakefield Asset Management's ACAD Position: Q1 2024 in Review

Wakefield Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 35,390 shares — an estimated $1.11M sold.

Wakefield Asset Management first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $1.11M in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Wakefield Asset Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Wakefield Asset Management sold 35,390 Acadia Pharmaceuticals shares in Q1 2024, an estimated $1.11M.
  • Wakefield Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Wakefield Asset Management's Acadia Pharmaceuticals position peaked at $1.11M in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Wakefield Asset Management's 13F filing for Q1 2024, filed 1 May 2024.